Reported zero revenue for the quarter ended March 31, 2026, compared to $150,000 in the first quarter of 2025. Realized a net loss of $511,000, or $0.02 per share, compared to a net loss of $363,000 in the prior year period. Recognized a $1,052,000 gain on an equity investment in ILiAD Biotechnologies following its $115 million Series B financing. Maintains a strong liquidity position with $34,589,000 in cash, cash equivalents, and marketable securities. Operating expenses increased to $1,415,000 from $795,000, driven by a $625,000 rise in litigation-related professional fees.